timothy sykes logo
PPBT Stock Jumps As Analyst Backs Risky Cancer Bet Thumbnail
G Google News

PPBT Stock Jumps As Analyst Backs Risky Cancer Bet

MATT MONACO•UPDATED SEP. 2, 2026, 7:48 AM ET
Reviewed by Jack Kelloggand Fact-checked by Tim Sykes

Purple Biotech Ltd. stocks have been trading up by 36.14 percent, driven by strong trial results and upbeat investor sentiment.

Key Takeaways

  • Purple Biotech reported Q2 2026 results featuring strong new preclinical data for its lead tri-specific antibody IM1240 and its CAPTN-3 platform.
  • The company disclosed a cash balance of just $6.1M, which is expected to fund operations only into mid-2027.
  • Management plans to advance IM1240 into a Phase 1 trial targeted for 2027, contingent on partnering or dilutive financing.
  • H.C. Wainwright cut Purple Biotech’s price target from $30 to $17 but maintained a Buy rating after Q2, citing low cash and sharply higher operating expenses.
  • H.C. Wainwright expects further preclinical data readouts from IM1240 and IM1305 through 2026.

Candlestick Chart

Live Update At 07:47:35 EDT: On Wednesday, September 02, 2026 Purple Biotech Ltd. stock [NASDAQ: PPBT] is trending up by 36.14%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

PPBT, or Purple Biotech Ltd., has been grinding higher on the chart despite real balance-sheet strain. Over the past few weeks, PPBT has climbed from around $1.50 to the $1.60–$1.70 area on the daily chart. That is a slow but steady uptrend, with higher lows forming from mid‑August into early September 2026. For a thin biotech, that kind of stair‑step pattern often tells traders that news flow and speculation are starting to line up.

Intraday, PPBT shows clear momentum bursts. On the latest 5‑minute data, the stock ripped from about $1.84 at 07:30 to highs above $2.40 before settling near $2.28. That is a textbook morning volatility spike, the kind short‑term traders live for.

More Breaking News

Fundamentally, Purple Biotech is still a pre‑revenue story. The key ratios show a tiny price‑to‑book near 0.28 and book value per share around $5.97, signaling deep “story stock” territory where the market heavily discounts assets. The balance sheet lists roughly $8.5M in cash and short‑term investments at 2024/12/31, but the latest Q2 2026 update pegs cash at only $6.1M, with operations funded only into mid‑2027. For traders, PPBT is a classic high‑risk, high‑volatility biotech: strong science narrative, very real funding overhang.

Why Traders Are Watching PPBT Now

PPBT is on screens because it sits right at the crossroads of scientific momentum and financial strain. In its Q2 2026 update, Purple Biotech highlighted strong new preclinical data for IM1240, its lead tri‑specific antibody, and progress on its CAPTN‑3 platform. That kind of early data often fuels big speculative runs in small‑cap biotech, and traders know how fast these names can squeeze when the crowd piles in.

But the same report laid out the hard part: Purple Biotech has only $6.1M in cash, enough to run the business into mid‑2027. Management wants to push IM1240 into a first‑in‑human Phase 1 trial in 2027, yet that plan depends on either a partnership or dilutive financing. For PPBT traders, that is the core tension. The pipeline might create serious value down the road, but the path almost certainly runs through one or more capital raises.

The Street is recalibrating. H.C. Wainwright cut its PPBT price target from $30 to $17, citing low cash and sharply higher Q2 operating expenses. At the same time, the firm kept a Buy rating and flagged more preclinical data coming from IM1240 and IM1305 through 2026. That tells traders the analyst still likes the science but now prices in more risk and delay. When a target gets slashed yet the rating stays positive, it often sets up choppy, news‑driven trading: spikes on data, pullbacks on financing fears.

With PPBT trading deep below that $17 target, day traders and swing traders are watching for liquidity surges around each data update, headline, or rumored deal.

Conclusion

PPBT sits in a classic biotech pressure cooker. On one side, Purple Biotech’s IM1240 and CAPTN‑3 platform are showing encouraging preclinical signs, with more data readouts expected through 2026 and a Phase 1 trial penciled in for 2027. On the other side, the company’s $6.1M cash balance, rising operating expenses, and mid‑2027 runway force traders to factor in dilution and deal risk on every move.

The H.C. Wainwright target cut from $30 to $17 while maintaining a Buy rating captures this trade perfectly: PPBT is still a speculative growth story, but the margin for error has shrunk. Any financing headline, partnership announcement, or surprise data set can swing the tape fast. The recent intraday spike from sub‑$2 to the $2.20s shows how quickly momentum traders can take charge when volume hits.

For active traders studying PPBT, the edge comes from preparation, not prediction. Track the clinical timelines, watch the cash disclosures, and map the key levels on both the daily and intraday charts. As millionaire penny stock trader and teacher Tim Sykes, says, “Preparation plus patience leads to big profits.”. As Tim Sykes likes to remind his community, “the market doesn’t care about your opinion, only your preparation.” PPBT is a live example of that idea—high potential, high risk, and a stock that rewards those who plan their trading and cut losses fast. This coverage is for educational and research purposes only, and every trader must make their own decisions.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”